Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
2.600
-0.080 (-2.99%)
At close: Jul 31, 2025, 4:00 PM
2.590
-0.010 (-0.38%)
After-hours: Jul 31, 2025, 4:22 PM EDT
Accolade Employees
Kiora Pharmaceuticals had 12 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,667
Profits / Employee
-$1,004,288
Market Cap
7.91M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12 | 0 | - |
| Dec 31, 2023 | 12 | 0 | - |
| Dec 31, 2022 | 12 | -2 | -14.29% |
| Dec 31, 2021 | 14 | 0 | - |
| Dec 31, 2020 | 14 | 4 | 40.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KPRX News
- 9 days ago - Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease - Newsfile Corp
- 2 months ago - Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia - Newsfile Corp
- 2 months ago - Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 - Newsfile Corp
- 4 months ago - Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference - Newsfile Corp
- 4 months ago - Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 - Newsfile Corp
- 5 months ago - Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting - Newsfile Corp
- 6 months ago - Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 - Newsfile Corp
- 6 months ago - Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema - Newsfile Corp